Curing All Patients with Acute Promyelocytic Leukemia: Are We There Yet?

被引：16

作者：

Baljeyic, Muhamed ^{[2
]}

Park, Jae H. ^{[1
]}

Stein, Eytan

Douer, Dan ^{[3
]}

Altman, Jessica K. ^{[4
]}

Tallman, Martin S. ^{[1
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, Weill Cornell Med Coll, Leukemia Serv, Dept Med, New York, NY 10065 USA

[2] New York Presbyterian Hosp, Weill Cornell Med Ctr, Dept Med, New York, NY 10065 USA

[3] Mem Sloan Kettering Canc Ctr, Acute Lymphoblast Leukemia Program, Dept Med, Weill Cornell Med Coll, New York, NY 10065 USA

[4] Northwestern Univ, Feinberg Sch Med, Dept Med, Robert H Lurie Comprehens Canc Ctr, Chicago, IL USA

来源：

HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA | 2011年 / 25卷 / 06期

关键词：

Acute promyelocytic leukemia; All-trans retinoic acid; Arsenic trioxide; Targeted therapies; Cure; TRANS-RETINOIC ACID; ACUTE MYELOGENOUS LEUKEMIA; EARLY HEMORRHAGIC DEATH; AGENT ARSENIC TRIOXIDE; RISK-ADAPTED TREATMENT; FRONT-LINE TREATMENT; RAR-ALPHA; ANTHRACYCLINE MONOCHEMOTHERAPY; MYELODYSPLASTIC SYNDROME; CONSOLIDATION THERAPY;

D O I：

10.1016/j.hoc.2011.10.002

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The introduction of all-trans retinoic acid to anthracycline-based chemotherapy has revolutionized the prognosis of patients with acute promyelocytic leukemia (APL). The introduction of arsenic trioxide enabled the therapeutic approach of rationally targeted frontline protocols with minimal or no traditional cytotoxic chemotherapy and without compromise of previously established outstanding outcomes with anthracycline-based regimens. Although most of the current investigative efforts in APL are focused on developing potentially curative therapy without the exposure to toxicities and risks of DNA-disrupting agents, the cure rate can further be increased by implementing meticulous supportive care strategies that counter early coagulopathy-related deaths.

引用

页码：1215 / +

页数：20

共 87 条

[1] Revisiting the differentiation paradigm in acute promyelocytic leukemia [J].

Ablain, Julien ;

de The, Hugues .

BLOOD, 2011, 117 (22) :5795-5802

[2]

Ades L, 2010, ASH ANN M ABSTR, V116, P13

[3] Is cytarabine useful in the treatment of acute promyelocytic leukemia?: Results of a randomized trial from the European Acute Promyelocytic Leukemia Group [J].

AdeS, Lionel ;

Chevret, Sylvie ;

Raffoux, Emmanuel ;

de Botton, Stephane ;

Guerci, Agnes ;

Pigneux, Arnaud ;

Stoppa, Anne Marie ;

Lamy, Thierry ;

Rigal-Huguet, Francoise ;

Vekhoff, Anne ;

Meyer-Monard, Sandrine ;

Maloisel, Frederic ;

Deconinck, Eric ;

Ferrant, Augustin ;

Thomas, Xavier ;

Fegueux, Nathalie ;

Chomienne, Christine ;

Dombret, Herve ;

Degos, Laurent ;

Fenaux, Pierre .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (36) :5703-5710

[4] Very long-term outcome of acute promyelocytic leukemia after treatment with all-trans retinoic acid and chemotherapy: the European APL Group experience [J].

Ades, Lionel ;

Guerci, Agnes ;

Raffoux, Emmanuel ;

Sanz, Miguel ;

Chevallier, Patrice ;

Lapusan, Simona ;

Recher, Christian ;

Thomas, Xavier ;

Rayon, Consuelo ;

Castaigne, Sylvie ;

Tournilhac, Olivier ;

de Botton, Stephane ;

Ifrah, Norbert ;

Cahn, Jean-Yves ;

Solary, Eric ;

Gardin, Claude ;

Fegeux, Nathalie ;

Bordessoule, Dominique ;

Ferrant, Augustin ;

Meyer-Monard, Sandrine ;

Vey, Norbert ;

Dombret, Herve ;

Degos, Laurent ;

Chevret, Sylvie ;

Fenaux, Pierre .

BLOOD, 2010, 115 (09) :1690-1696

[5] Therapy-related MDS and AML in acute promyelocytic leukemia [J].

Andersen, MK ;

Pedersen-Bjergaard, J .

BLOOD, 2002, 100 (05) :1928-1929

[6]

[Anonymous], 2009, BLOOD

[7]

[Anonymous], BLOOD S1

[8] Analysis of prognostic factors in newly diagnosed acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy [J].

Asou, N ;

Adachi, K ;

Tamura, J ;

Kanamaru, A ;

Kageyama, S ;

Hiraoka, A ;

Omoto, E ;

Akiyama, H ;

Tsubaki, K ;

Saito, K ;

Kuriyama, K ;

Oh, H ;

Kitano, K ;

Miyawaki, S ;

Takeyama, K ;

Yamada, O ;

Nishikawa, K ;

Takahashi, M ;

Matsuda, S ;

Ohtake, S ;

Suzushima, H ;

Emi, N ;

Ohno, R .

JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (01) :78-85

[9] A randomized study with or without intensified maintenance chemotherapy in patients with acute promyelocytic leukemia who have become negative for PML-RARα transcript after consolidation therapy:: The Japan Adult Leukemia Study Group (JALSG) APL97 study [J].

Asou, Norio ;

Kishimoto, Yuji ;

Kiyoi, Hitoshi ;

Okada, Masaya ;

Kawai, Yasukazu ;

Tsuzuki, Motohiro ;

Horikawa, Kentaro ;

Matsuda, Mitsuhiro ;

Shinagawa, Katsuji ;

Kobayashi, Tohru ;

Ohtake, Shigeki ;

Nishimura, Miki ;

Takahashi, Masatomo ;

Yagasaki, Fumiharu ;

Takeshita, Akihiro ;

Kimura, Yukihiko ;

Lwanaga, Masako ;

Naoe, Tomoki ;

Ohno, Ryuzo .

BLOOD, 2007, 110 (01) :59-66

[10] AIDA (all-trans retinoic acid plus idarubicin) in newly diagnosed acute promyelocytic leukemia: A Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Pilot study [J].

Avvisati, G ;

LoCoco, F ;

Diverio, D ;

Falda, M ;

Ferrara, F ;

Lazzarino, M ;

Russo, D ;

Petti, MC ;

Mandelli, F .

BLOOD, 1996, 88 (04) :1390-1398

← 1 2 3 4 5 6 7 8 9 →